Search

Your search keyword '"Chin I. Chen"' showing total 2 results
Start Over Author "Chin I. Chen" Publisher elsevier
2 results on '"Chin I. Chen"'

1. Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70–100 mg/dL in Taiwan

Author

Fang-Ju Lin, Kou-Gi Shyu, I-Chang Hsieh, Wayne Huey-Herng Sheu, Shih-Te Tu, Shoou-Jeng Yeh, Chin-I Chen, Kuo-Cheng Lu, Chia-Chao Wu, Wen-Yi Shau, Timothy J. Inocencio, Yao-Chun Wen, and Hung-I Yeh

Subjects
Statin, Secondary prevention, Low-density lipoprotein cholesterol, Coronary artery disease, Cost-effectiveness analysis, Medicine (General), R5-920
Abstract

Background: The recommended target low-density lipoprotein cholesterol (LDL-C) level for coronary artery disease (CAD) patients has been lowered from 100 to 70 mg/dL in several clinical guidelines for secondary prevention. We aimed to assess whether initiating statin treatment in CAD patients with baseline LDL-C 70–100 mg/dL in Taiwan could be cost-effective. Methods: A Markov model was developed to simulate a hypothetical cohort of CAD patients with a baseline LDL-C level of 90 mg/dL. The incidence and recurrence of MI and stroke related to specific LDL-C levels as well as the statin effect, mortality rate, and health state utilities were obtained from the literature. The direct medical costs and rate of fatal events were derived from the national claims database. The incremental cost-effectiveness ratio (ICER) per quality-adjusted life years (QALYs) was calculated, and sensitivity analyses were performed. Results: Moderate-intensity statin use, a treatment regimen expected to achieve LDL

Published
2020
Full Text
View/download PDF

2. Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70–100 mg/dL in Taiwan

Author

Wayne Huey-Herng Sheu, Kou-Gi Shyu, I-Chang Hsieh, Shoou-Jeng Yeh, Hung-I Yeh, Shih-Te Tu, Chin-I Chen, Wen-Yi Shau, Timothy J. Inocencio, Fang-Ju Lin, Chia-Chao Wu, Yao-Chun Wen, and Kuo-Cheng Lu

Subjects
medicine.medical_specialty, Statin, Cost effectiveness, medicine.drug_class, Cost-Benefit Analysis, Taiwan, Coronary artery disease, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Low-density lipoprotein cholesterol, Stroke, health care economics and organizations, lcsh:R5-920, business.industry, Mortality rate, Incidence (epidemiology), Secondary prevention, Cost-effectiveness analysis, General Medicine, Cholesterol, LDL, medicine.disease, 030220 oncology & carcinogenesis, Cohort, 030211 gastroenterology & hepatology, Quality-Adjusted Life Years, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, lcsh:Medicine (General)
Abstract

Background: The recommended target low-density lipoprotein cholesterol (LDL-C) level for coronary artery disease (CAD) patients has been lowered from 100 to 70 mg/dL in several clinical guidelines for secondary prevention. We aimed to assess whether initiating statin treatment in CAD patients with baseline LDL-C 70–100 mg/dL in Taiwan could be cost-effective. Methods: A Markov model was developed to simulate a hypothetical cohort of CAD patients with a baseline LDL-C level of 90 mg/dL. The incidence and recurrence of MI and stroke related to specific LDL-C levels as well as the statin effect, mortality rate, and health state utilities were obtained from the literature. The direct medical costs and rate of fatal events were derived from the national claims database. The incremental cost-effectiveness ratio (ICER) per quality-adjusted life years (QALYs) was calculated, and sensitivity analyses were performed. Results: Moderate-intensity statin use, a treatment regimen expected to achieve LDL

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results